This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Quest Diagnostics' (DGX) New Pact to Advance Cancer Screening
by Zacks Equity Research
Quest Diagnostics' (DGX) latest partnership will increase the likelihood that Americans will eventually have an easy, reliable and accessible way to check for colorectal cancer.
Abbott (ABT) Benefits From Innovation Amid FX Headwinds
by Zacks Equity Research
Abbott's (ABT) mAbxience collaboration is likely to help introduce cutting-edge medicines in the areas of oncology, women's health and respiratory diseases.
Teleflex (TFX) Enrolls First Patient in ACCESS-MANTA Registry
by Zacks Equity Research
Teleflex's (TFX) ACCESS-MANTA Registry is likely to examine the contemporary on-label use of the MANTA VCD.
Medtronic (MDT) Q2 Earnings Beat Estimates, 2024 View Up
by Zacks Equity Research
Medtronic (MDT) Q2 results reflect broad strength across businesses and geographies, benefiting from durable fundamentals.
Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now
by Zacks Equity Research
Investors are optimistic about Myriad Genetics (MYGN) on recent partnerships and growth in testing volumes.
Zimmer Biomet's (ZBH) Knee Sales Robust, Macro Woes Hurt
by Zacks Equity Research
Zimmer Biomet (ZBH) is working to strengthen its foothold in emerging markets that provide long-term opportunities for growth.
Boston Scientific (BSX) Closes the Relievant Medsystems Buyout
by Zacks Equity Research
Boston Scientific (BSX) expands the neuromodulation portfolio with the acquisition of Relievant Medsystems.
Here's Why Investors Should Retain STERIS (STE) Stock for Now
by Zacks Equity Research
STERIS' (STE) Healthcare segment continues to benefit from procedure volume recovery.
National Vision's (EYE) Market Expansion Aids, Inflation Ails
by Zacks Equity Research
National Vision (EYE) is expanding sales by the continued rollout of its remote medicine technology.
Myriad Genetics (MYGN) Expands Pharma Services With New Pact
by Zacks Equity Research
Myriad Genetics (MYGN) will market the Personalis ImmunoID NeXT ultra-comprehensive biomarker discovery platform to its pharmaceutical partners with a new collaboration.
Medtronic's (MDT) Symplicity Spyral RDN System Gets FDA Boost
by Zacks Equity Research
Medtronic (MDT) receives the FDA approval for Symplicity blood pressure procedure for the treatment of hypertension.
Paragon 28 (FNA) BEAST Cortical Fibers Launch Boosts Biologics
by Zacks Equity Research
Paragon 28's (FNA) BEAST Cortical Fibers' advanced processing capability ensures the preservation of native bone morphogenic proteins and other growth factors crucial for bone formation.
Nemaura (NMRD) to Expand in UK With Metabolic Health Program
by Zacks Equity Research
The latest program leverages Nemaura's (NMRD) world-first daily wear non-invasive CGM technology, providing individuals with real-time insights into their body's glucose dynamics.
Neogen's (NEOG) Innovation Aids, Currency Headwind Stays
by Zacks Equity Research
Neogen (NEOG) is progressing well in terms of picking the right growth markets and gaining a bigger share of those markets.
Charles River (CRL) Widens CliniPrime GMP Suite With New Launch
by Zacks Equity Research
Charles River (CRL) brings CliniPrime Cryopreserved Leukopaks for cell therapy development and manufacturing.
Paragon 28 (FNA) New Staple System Expands Ankle Device Line
by Zacks Equity Research
Paragon 28's (FNA) JAWS Great White Staple System is claimed to have 400 times greater fatigue life compared to competitors under similar load conditions.
Omnicell's (OMCL) Portfolio Expansion Aids Amid Macro Woes
by Zacks Equity Research
Omnicell (OMCL) accelerates its shift to cloud-based solutions and tech-enabled services through the launch of Inventory Optimization Service and Central Pharmacy Dispensing Services.
Here's Why You Should Retain Omnicell (OMCL) Stock Now
by Zacks Equity Research
Investors are optimistic about Omnicell (OMCL) due to its technology and innovative solutions.
Illumina (ILMN) Launches Initiative on Pathogen Sequencing
by Zacks Equity Research
Illumina (ILMN) introduces a new initiative to drive more equitable access to genomics globally.
HAE or SYK: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HAE vs. SYK: Which Stock Is the Better Value Option?
Prestige Consumer's (PBH) Brand Building, Innovation Aid Growth
by Zacks Equity Research
Prestige Consumer's (PBH) long-term brand-building efforts, efficient marketing, channel development and innovation help the company to continually hold a leading market share position.
QIAGEN (QGEN) Launches QIAcuity Kits and Software Update
by Zacks Equity Research
QIAGEN's (QGEN) new QIAcuity kits are likely to expand application areas and foster digital PCR adoption.
Here's Why Investors Should Buy Alcon (ALC) Stock Right Now
by Zacks Equity Research
Investors continue to be optimistic about Alcon (ALC), backed by a competitive product portfolio and strong commercial execution.
IDEXX's (IDXX) Upcoming Launch to Detect Canine Leishmaniosis
by Zacks Equity Research
IDEXX (IDXX) expands the SNAP franchise with a comprehensive solution for detecting canine leishmaniosis.
Is Haemonetics (HAE) a Solid Growth Stock? 3 Reasons to Think "Yes"
by Zacks Equity Research
Haemonetics (HAE) could produce exceptional returns because of its solid growth attributes.